Design of siRNA therapeutics from the molecular scale

Pharmaceuticals

Volumn 6, Issue 4, 2013, Pages 440-468

  Angart, Phillip ^a   Vocelle, Daniel ^a   Chan, Christina ^a   Patrick Walton, S ^a  

^a Michigan State University   (United States)

Author keywords

Delivery vehicle design; Liver cancer; RNAi; siRNA design; siRNA therapeutic

Indexed keywords

DRUG CARRIER; MESSENGER RNA; PLACEBO; SMALL INTERFERING RNA; SORAFENIB; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; CYTOPLASM; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MECHANISM; GENE SILENCING; GENE TARGETING; GENETIC STABILITY; HUMAN; HYBRIDIZATION; IMMUNOGENICITY; LIVER CELL CARCINOMA; PRACTICE GUIDELINE; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TARGET CELL;

EID: 84875908270     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6040440     Document Type: Review

References (249)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M, Globocan 2008 v2.0, cancer incidence and mortality worldwide: Iarc cancerbase no. 10. Available online: http://globocan.iarc.fr/ (accessed on 26 November 2012).
2. Americancancersociety. Cancer facts& figures 2012. Available online: http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012/ (accessd on 26 November 2012).
3. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-390.
4. Zhu, A.X.; Duda, D.G.; Sahani, D.V.; Jain, R.K. Hcc and angiogenesis: Possible targets and future directions. Nat. Rev. Clin. Oncol. 2011, 8, 292-301.
5. Villanueva, A.; Llovet, J.M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011, 140, 1410-1426.
6. Burnett, J.C.; Rossi, J.J.; Tiemann, K. Current progress of sirna/shrna therapeutics in clinical trials. Biotechnol. J. 2011, 6, 1130-1146.
7. Haussecker, D. The business of rnai therapeutics in 2012. Mol. Ther. Nucleic Acids 2012, 1, e8.
8. Wei, J.; Jones, J.; Kang, J.; Card, A.; Krimm, M.; Hancock, P.; Pei, Y.; Ason, B.; Payson, E.; Dubinina, N, et al. Rna-induced silencing complex-bound small interfering rna is a determinant of rna interference-mediated gene silencing in mice. Mol. Pharmacol. 2011, 79, 953-963.
9. Bartlett, D.W. Insights into the kinetics of sirna-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006, 34, 322-333.
10. Spiller, D.G.; Giles, R.V.; Broughton, C.M.; Grzybowski, J.; Ruddell, C.J.; Tidd, D.M.; Clark, R.E. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses. Antisense Nucleic Acid Drug Dev. 1998, 8, 281-293.
11. Larsson, E.; Sander, C.; Marks, D. Mrna turnover rate limits sirna and microrna efficacy. Mol. Syst. Biol. 2010, 6, 1-9.
12. Kennedy, S.; Wang, D.; Ruvkun, G. A conserved sirna-degrading rnase negatively regulates rna interference in c. Elegans. Nature 2004, 427, 645-649.
13. Bian, Y.; Zhou, W.; Zhao, Y.; Li, X.; Geng, W.; Hao, R.; Yang, Q.; Huang, W. High-dose sirnas upregulate mouse eri-1 at both transcription and posttranscription levels. PLoS ONE 2011, 6, e26466.
14. Caffrey, D.R.; Zhao, J.; Song, Z.; Schaffer, M.E.; Haney, S.A.; Subramanian, R.R.; Seymour, A.B.; Hughes, J.D. Sirna off-target effects can be reduced at concentrations that match their individual potency. PLoS ONE 2011, 6, e21503.
15. Calera, M.R.; Venkatakrishnan, A.; Kazlauskas, A. Ve-cadherin increases the half-life of vegf receptor 2. Exp. Cell Res. 2004, 300, 248-256.
16. Schlessinger, J. The epidermal growth factor receptor as a multifunctional allosteric protein. Biochemistry 1988, 27, 3119-3123.
17. Dhut, S.; Chaplin, T.; Young, B.D. Bcr-abl and bcr proteins: Biochemical characterization and localization. Leukemia 1990, 4, 745-750.
18. Wang, P.Y.; Rao, J.N.; Zou, T.; Liu, L.; Xiao, L.; Yu, T.X.; Turner, D.J.; Gorospe, M.; Wang, J.Y. Post-transcriptional regulation of mek-1 by polyamines through the rna-binding protein hur modulating intestinal epithelial apoptosis. Biochem. J. 2010, 426, 293-306.
19. Keating, M.T.; Williams, L.T. Processing of the platelet-derived growth factor receptor. Biosynthetic and degradation studies using anti-receptor antibodies. J. Biol. Chem. 1987, 262, 7932-7937.
20. Yang, E.; van Nimwegen, E.; Zavolan, M.; Rajewsky, N.; Schroeder, M.; Magnasco, M.; Darnell, J.E. Decay rates of human mrnas: Correlation with functional characteristics and sequence attributes. Genome Res. 2003, 13, 1863-1872.
21. Llovet, J.M.; Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48, 1312-1327.
22. Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W.S.; Khvorova, A. Rational sirna design for rna interference. Nat. Biotechnol. 2004, 22, 326-330.
23. Jackson, A.L.; Bartz, S.R.; Schelter, J.; Kobayashi, S.V.; Burchard, J.; Mao, M.; Li, B.; Cavet, G.; Linsley, P.S. Expression profiling reveals off-target gene regulation by rnai. Nat. Biotechnol. 2003, 21, 635-637.
24. Naito, Y.; Ui-Tei, K. Sirna design software for a target gene-specific rna interference. Front. Genet. 2012, 3, 102.
25. Bernstein, E.; Caudy, A.A.; Hammond, S.M.; Hannon, G.J. Role for a bidentate ribonuclease in the initiation step of rna interference. Nature 2001, 409, 363-366.
26. Zamore, P.D.; Tuschl, T.; Sharp, P.A.; Bartel, D.P. Rnai: Double-stranded rna directs the atp-dependent cleavage of mrna at 21 to 23 nucleotide intervals. Cell 2000, 101, 25-33.
27. Nykänen, A.; Haley, B.; Zamore, P.D. Atp requirements and small interfering rna structure in the rna interference pathway. Cell 2001, 107, 309-321.
28. Elbashir, S.M.; Martinez, J.; Patkaniowska, A.; Lendeckel, W.; Tuschl, T. Functional anatomy of sirnas for mediating efficient rnai in drosophila melanogaster embryo lysate. EMBO J. 2001, 20, 6877-6888.
29. Lima, W.F.; Murray, H.; Nichols, J.G.; Wu, H.; Sun, H.; Prakash, T.P.; Berdeja, A.R.; Gaus, H.J.; Crooke, S.T. Human dicer binds short single-strand and double-strand rna with high affinity and interacts with different regions of the nucleic acids. J. Biol. Chem. 2009, 284, 2535-2548.
30. Sakurai, K.; Amarzguioui, M.; Kim, D.; Alluin, J.; Heale, B.; Song, M.; Gatignol, A.; Behlke, M.A.; Rossi, J.J. A role for human dicer in pre-risc loading of sirnas. Nucleic Acids Res. 2011, 39, 1510-1525.
31. Liu, Q.H.; Rand, T.A.; Kalidas, S.; Du, F.H.; Kim, H.E.; Smith, D.P.; Wang, X.D. R2d2, a bridge between the initiation and effector steps of the drosophila rnai pathway. Science 2003, 301, 1921-1925.
32. Tomari, Y.; Du, T.; Haley, B.; Schwarz, D.; Bennett, R.; Cook, H.; Koppetsch, B.; Theurkauf, W.; Zamore, P. Risc assembly defects in the drosophila rnai mutant armitage. Cell 2004, 116, 831-841.
33. Tomari, Y.; Matranga, C.; Haley, B.; Martinez, N.; Zamore, P.D. A protein sensor for sirna asymmetry. Science 2004, 306, 1377-1380.
34. Chendrimada, T.; Gregory, R.; Kumaraswamy, E.; Norman, J.; Cooch, N.; Nishikura, K.; Shiekhattar, R. Trbp recruits the dicer complex to ago2 for microrna processing and gene silencing. Nature 2005, 436, 740-744.
35. Hammond, S.M.; Bernstein, E.; Beach, D.; Hannon, G.J. An rna-directed nuclease mediates post-transcriptional gene silencing in drosophila cells. Nature 2000, 404, 293-296.
36. MacRae, I.J.; Ma, E.; Zhou, M.; Robinson, C.V.; Doudna, J.A. In vitro reconstitution of the human risc-loading complex. Proc. Natl. Acad. Sci. USA 2008, 105, 512-517.
37. Gredell, J.A.; Dittmer, M.J.; Wu, M.; Chan, C.; Walton, S.P. Recognition of sirna asymmetry by tar rna binding protein. Biochemistry 2010, 49, 3148-3155.
38. Noland, C.L.; Ma, E.; Doudna, J.A. Sirna repositioning for guide strand selection by human dicer complexes. Mol. Cell 2011, 43, 110-121.
39. Khvorova, A.; Reynolds, A.; Jayasena, S.D. Functional sirnas and mirnas exhibit strand bias. Cell 2003, 115, 209-216.
40. Schwarz, D.; Hutvagner, G.; Du, T.; Xu, Z.; Aronin, N.; Zamore, P. Asymmetry in the assembly of the rnai enzyme complex. Cell 2003, 115, 199-208.
41. Hamilton, A.; Baulcombe, D. A species of small antisense rna in posttranscriptional gene silencing in plants. Science 1999, 286, 950-952.
42. Elbashir, S.M.; Lendeckel, W.; Tuschl, T. Rna interference is mediated by 21-and 22-nucleotide rnas. Genes Dev. 2001, 15, 188-200.
43. Rand, T.A.; Petersen, S.; Du, F.; Wang, X. Argonaute2 cleaves the anti-guide strand of sirna during risc activation. Cell 2005, 123, 621-629.
44. Leuschner, P.J.F.; Ameres, S.L.; Kueng, S.; Martinez, J. Cleavage of the sirna passenger strand during risc assembly in human cells. EMBO Rep. 2006, 7, 314-320.
45. Matranga, C.; Tomari, Y.; Shin, C.; Bartel, D.; Zamore, P. Passenger-strand cleavage facilitates assembly of sirna into ago2-containing rnai enzyme complexes. Cell 2005, 123, 607-620.
46. Yoda, M.; Kawamata, T.; Paroo, Z.; Ye, X.; Iwasaki, S.; Liu, Q.; Tomari, Y. Atp-dependent human risc assembly pathways. Nat. Struct. Mol. Biol. 2010, 17, 17-23.
47. Rivas, F.V.; Tolia, N.H.; Song, J.J.; Aragon, J.P.; Liu, J.D.; Hannon, G.J.; Joshua-Tor, L. Purified argonaute2 and an sirna form recombinant human risc. Nat. Struct. Mol. Biol. 2005, 12, 340-349.
48. Haley, B.; Zamore, P.D. Kinetic analysis of the rnai enzyme complex. Nat. Struct. Mol. Biol. 2004, 11, 599-606.
49. Liu, J.D.; Carmell, M.A.; Rivas, F.V.; Marsden, C.G.; Thomson, J.M.; Song, J.J.; Hammond, S.M.; Joshua-Tor, L.; Hannon, G.J. Argonaute2 is the catalytic engine of mammalian rnai. Sci. Signal. 2004, 305, 1437-1437.
50. Snead, N.M.; Rossi, J.J. Biogenesis and function of endogenous and exogenous sirnas. Wiley Interdiscip. Rev. RNA 2010, 1, 117-131.
51. Carthew, R.W.; Sontheimer, E.J. Origins and mechanisms of mirnas and sirnas. Cell 2009, 136, 642-655.
52. Grimm, D.; Streetz, K.L.; Jopling, C.L.; Storm, T.A.; Pandey, K.; Davis, C.R.; Marion, P.; Salazar, F.; Kay, M.A. Fatality in mice due to oversaturation of cellular microrna/short hairpin rna pathways. Nature 2006, 441, 537-541.
53. Frank, F.; Sonenberg, N.; Nagar, B. Structural basis for 5'-nucleotide base-specific recognition of guide rna by human ago2. Nature 2010, 465, 818-822.
54. Walton, S.P.; Wu, M.; Gredell, J.A.; Chan, C. Designing highly active sirnas for therapeutic applications. FEBS J. 2010, 277, 4806-4813.
55. Betancur, J.G.; Tomari, Y. Dicer is dispensable for asymmetric risc loading in mammals. RNA 2012, 18, 24-30.
56. Hutvagner, G. Small rna asymmetry in rnai: Function in risc assembly and gene regulation. FEBS Lett. 2005, 579, 5850-5857.
57. Lu, Z.J.; Mathews, D.H. Efficient sirna selection using hybridization thermodynamics. Nucleic Acids Res. 2008, 36, 640-647.
58. Ui-Tei, K.; Naito, Y.; Takahashi, F.; Haraguchi, T.; Ohki-Hamazaki, H.; Juni, A.; Ueda, R.; Saigo, K. Guidelines for the selection of highly effective sirna sequences for mammalian and chick rna interference. Nucleic Acids Res. 2004, 32, 936-948.
59. Jagla, B.; Aulner, N.; Kelly, P.D.; Song, D.; Volchuk, A.; Zatorski, A.; Shum, D.; Mayer, T.; de Angelis, D.A.; Ouerfelli O, et al. Sequence characteristics of functional sirnas. RNA 2005, 11, 864-872.
60. Huesken, D.; Lange, J.; Mickanin, C.; Weiler, J.; Asselbergs, F.; Warner, J.; Meloon, B.; Engel, S.; Rosenberg, A.; Cohen, D, et al. Design of a genome-wide sirna library using an artificial neural network. Nat. Biotechnol. 2005, 23, 995-1001.
61. Ladunga, I. More complete gene silencing by fewer sirnas: Transparent optimized design and biophysical signature. Nucleic Acids Res. 2006, 35, 433-440.
62. Shabalina, S.A.; Spiridonov, A.N.; Ogurtsov, A.Y. Computational models with thermodynamic and composition features improve sirna design. BMC Bioinformatics 2006, 7.
63. Amarzguioui, M.; Prydz, H. An algorithm for selection of functional sirna sequences. Biochem. Biophys. Res. Commun. 2004, 316, 1050-1058.
64. Gong, W.; Ren, Y.; Xu, Q.; Wang, Y.; Lin, D.; Zhou, H.; Li, T. Integrated sirna design based on surveying of features associated with high rnai effectiveness. BMC Bioinformatics 2006, 7, 516.
65. Takasaki, S.; Kotani, S.; Konagaya, A. An effective method for selecting sirna target sequences in mammalian cells. Cell Cycle 2004, 3, 788-793.
66. Holen, T. Efficient prediction of sirnas with sirnarules 1.0: An open-source java approach to sirna algorithms. RNA 2006, 12, 1620-1625.
67. Takasaki, S. Selecting effective sirna target sequences by using bayes' theorem. Comput. Biol. Chem. 2009, 33, 368-372.
68. Katoh, T.; Suzuki, T. Specific residues at every third position of sirna shape its efficient rnai activity. Nucleic Acids Res. 2007, 35, e27.
69. Seitz, H.; Tushir, J.S.; Zamore, P.D. A 5'-uridine amplifies mirna/mirna* asymmetry in drosophila by promoting rna-induced silencing complex formation. Silence 2011, 2, 4.
70. Brown, K.M.; Chu, C.Y.; Rana, T.M. Target accessibility dictates the potency of human risc. Nat. Struct. Mol. Biol. 2005, 12, 469-470.
71. Ameres, S.L.; Martinez, J.; Schroeder, R. Molecular basis for target rna recognition and cleavage by human risc. Cell 2007, 130, 101-112.
72. Mathews, D.; Sabina, J.; Zuker, M.; Turner, D. Expanded sequence dependence of thermodynamic parameters improves prediction of rna secondary structure. J. Mol. Biol. 1999, 288, 911-940.
73. Ding, Y.; Chan, C.Y.; Lawrence, C.E. Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Res. 2004, 32, W135-W141.
74. Tafer, H.; Ameres, S.L.; Obernosterer, G.; Gebeshuber, C.A.; Schroeder, R.; Martinez, J.; Hofacker, I.L. The impact of target site accessibility on the design of effective sirnas. Nat. Biotechnol. 2008, 26, 578-583.
75. Gredell, J.; Berger, A.; Walton, S. Impact of target mrna structure on sirna silencing efficiency: A large-scale study. Biotechnol. Bioeng. 2008, 100, 744-755.
76. Vickers, T.A.; Koo, S.; Bennett, C.F.; Crooke, S.T.; Dean, N.M.; Baker, B.F. Efficient reduction of target rnas by small interfering rna and rnase h-dependent antisense agents. A comparative analysis. J. Biol. Chem. 2003, 278, 7108-7118.
77. Bohula, E.A.; Salisbury, A.J.; Sohail, M.; Playford, M.P.; Riedemann, J.; Southern, E.M.; Macaulay, V.M. The efficacy of small interfering rnas targeted to the type 1 insulin-like growth factor receptor (igf1r) is influenced by secondary structure in the igf1r transcript. J. Biol. Chem. 2003, 278, 15991-15997.
78. Overhoff, M.; Alken, M.; Far, R.K.-K.; Lemaitre, M.; Lebleu, B.; Sczakiel, G.; Robbins, I. Local rna target structure influences sirna efficacy: A systematic global analysis. J. Mol. Biol. 2005, 348, 871-881.
79. Schubert, S.; Grünweller, A.; Erdmann, V.A.; Kurreck, J. Local rna target structure influences sirna efficacy: Systematic analysis of intentionally designed binding regions. J. Mol. Biol. 2005, 348, 883-893.
80. Shao, Y.; Chan, C.Y.; Maliyekkel, A.; Lawrence, C.E.; Roninson, I.B.; Ding, Y. Effect of target secondary structure on rnai efficiency. RNA 2007, 13, 1631-1640.
81. Yoshinari, K.; Miyagishi, M.; Taira, K. Effects on rnai of the tight structure, sequence and position of the targeted region. Nucleic Acids Res. 2004, 32, 691-699.
82. Sledz, C.A.; Holko, M.; de Veer, M.J.; Silverman, R.H.; Williams, B.R.G. Activation of the interferon system by short-interfering rnas. Nat. Cell Biol. 2003, 5, 834-839.
83. Samuel-Abraham, S.; Leonard, J.N. Staying on message: Design principles for controlling nonspecific responses to sirna. FEBS J. 2010, 277, 4828-4836.
84. Jackson, A. Recognizing and avoiding sirna off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 2010, 9, 57-67.
85. Robbins, M.; Judge, A.; Liang, L. 2'-o-methyl-modified rnas act as tlr7 antagonists. Mol. Ther. 2007, 15, 1663-1669.
86. Kodym, R.; Kodym, E.; Story, M.D. 2'-5'-oligoadenylate synthetase is activated by a specific rna sequence motif. Biochem. Biophys. Res. Commun. 2009, 388, 317-322.
87. Manche, L.; Green, S.R.; Schmedt, C.; Mathews, M.B. Interactions between double-stranded rna regulators and the protein kinase dai. Mol. Cell. Biol. 1992, 12, 5238-5248.
88. Bevilacqua, P.C.; Cech, T.R. Minor-groove recognition of double-stranded rna by the double-stranded rna-binding domain from the rna-activated protein kinase pkr. Biochemistry 1996, 35, 9983-9994.
89. Marques, J.T.; Devosse, T.; Wang, D.; Zamanian-Daryoush, M.; Serbinowski, P.; Hartmann, R.; Fujita, T.; Behlke, M.A.; Williams, B.R. A structural basis for discriminating between self and nonself double-stranded rnas in mammalian cells. Nat. Biotechnol. 2006, 24, 559-565.
90. Kato, H.; Takeuchi, O.; Mikamo-Satoh, E.; Hirai, R.; Kawai, T.; Matsushita, K.; Hiiragi, A.; Dermody, T.S.; Fujita, T.; Akira, S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-i and melanoma differentiation-associated gene 5. J. Exp. Med. 2008, 205, 1601-1610.
91. Gantier, M.P.; Williams, B.R.G. The response of mammalian cells to double-stranded rna. Cytokine Growth Factor Rev. 2007, 18, 363-371.
92. Nallagatla, S.R.; Hwang, J.; Toroney, R.; Zheng, X.; Cameron, C.E.; Bevilacqua, P.C. 5'-triphosphate-dependent activation of pkr by rnas with short stem-loops. Science 2007, 318, 1455-1458.
93. Takeda, K.; Kaisho, T.; Akira, S. Toll-like receptors. Annu. Rev. Immunol. 2003, 21, 335-376.
94. Weber, C.; Müller, C.; Podszuweit, A.; Montino, C.; Vollmer, J.; Forsbach, A. Toll-like receptor (tlr) 3 immune modulation by unformulated small interfering rna or DNA and the role of cd14 (in tlr-mediated effects). Immunology 2012, 136, 64-77.
95. Alexopoulou, L.; Holt, A.C.; Medzhitov, R.; Flavell, R.A. Recognition of double-stranded rna and activation of nf-kappab by toll-like receptor 3. Nature 2001, 413, 732-738.
96. Kariko, K.; Bhuyan, P.; Capodici, J.; Weissman, D. Small interfering rnas mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 2004, 172, 6545-6549.
97. Heil, F.; Hemmi, H.; Hochrein, H.; Ampenberger, F.; Kirschning, C.; Akira, S.; Lipford, G.; Wagner, H.; Bauer, S. Species-specific recognition of single-stranded rna via toll-like receptor 7 and 8. Science 2004, 303, 1526-1529.
98. Judge, A.D.; Sood, V.; Shaw, J.R.; Fang, D.; McClintock, K.; MacLachlan, I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic sirna. Nat. Biotechnol. 2005, 23, 457-462.
99. Jackson, A.L.; Burchard, J.; Leake, D.; Reynolds, A.; Schelter, J.; Guo, J.; Johnson, J.M.; Lim, L.; Karpilow, J.; Nichols, K, et al. Position-specific chemical modification of sirnas reduces "off-target" transcript silencing. RNA 2006, 12, 1197-1205.
100. Diebold, S.S.; Kaisho, T.; Hemmi, H.; Akira, S.; Reis e Sousa, C. Innate antiviral responses by means of tlr7-mediated recognition of single-stranded rna. Science 2004, 303, 1529-1531.
101. Diebold, S.S.; Massacrier, C.; Akira, S.; Paturel, C.; Morel, Y.; Reis e Sousa, C. Nucleic acid agonists for toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 2006, 36, 3256-3267.
102. Goodchild, A.; Nopper, N.; King, A.; Doan, T.; Tanudji, M.; Arndt, G.M.; Poidinger, M.; Rivory, L.P.; Passioura, T. Sequence determinants of innate immune activation by short interfering rnas. BMC Immunol. 2009, 10.
103. Kleinman, M.E.; Yamada, K.; Takeda, A.; Chandrasekaran, V.; Nozaki, M.; Baffi, J.Z.; Albuquerque, R.J.C.; Yamasaki, S.; Itaya, M.; Pan, Y.; Appukuttan, B.; Gibbs, D.; Yang, Z.; Karikó, K.; Ambati, B.K.; Wilgus, T.A.; DiPietro, L.A.; Sakurai, E.; Zhang, K.; Smith, J.R.; Taylor, E.W.; Ambati, J. Sequence- and target-independent angiogenesis suppression by sirna via tlr3. Nature 2008, 452, 591-597.
104. Reynolds, A.; Anderson, E.M.; Vermeulen, A.; Fedorov, Y.; Robinson, K.; Leake, D.; Karpilow, J.; Marshall, W.S.; Khvorova, A. Induction of the interferon response by sirna is cell type- and duplex length-dependent. RNA 2006, 12, 988-993.
105. Forsbach, A.; Nemorin, J.-G.; Montino, C.; Müller, C.; Samulowitz, U.; Vicari, A.P.; Jurk, M.; Mutwiri, G.K.; Krieg, A.M.; Lipford, G.B.; Vollmer, J. Identification of rna sequence motifs stimulating sequence-specific tlr8-dependent immune responses. J. Immunol. 2008, 180, 3729-3738.
106. Sioud, M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded sirnas is sequence-dependent and requires endosomal localization. J. Mol. Biol. 2005, 348, 1079-1090.
107. Hornung, V.; Guenthner-Biller, M.; Bourquin, C.; Ablasser, A.; Schlee, M.; Uematsu, S.; Noronha, A.; Manoharan, M.; Akira, S.; de Fougerolles, A.; Endres, S.; Hartmann, G. Sequence-specific potent induction of ifn-α by short interfering rna in plasmacytoid dendritic cells through tlr7. Nat. Med. 2005, 11, 263-270.
108. Jurk, M.; Chikh, G.; Schulte, B.; Kritzler, A.; Richardt-Pargmann, D.; Lampron, C.; Luu, R.; Krieg, A.M.; Vicari, A.P.; Vollmer, J. Immunostimulatory potential of silencing rnas can be mediated by a non-uridine-rich toll-like receptor 7 motif. Nucleic Acid Ther. 2011, 21, 201-214.
109. Fedorov, Y.; Anderson, E.M.; Birmingham, A.; Reynolds, A.; Karpilow, J.; Robinson, K.; Leake, D.; Marshall, W.S.; Khvorova, A. Off-target effects by sirna can induce toxic phenotype. RNA 2006, 12, 1188-1196.
110. Shafer, R.H.; Smirnov, I. Biological aspects of DNA/rna quadruplexes. Biopolymers 2000, 56, 209-227.
111. Doench, J.G.; Petersen, C.P.; Sharp, P.A. Sirnas can function as mirnas. Genes Dev. 2003, 17, 438-442.
112. Lambert, N.J.; Gu, S.G.; Zahler, A.M. The conformation of microrna seed regions in native micrornps is prearranged for presentation to mrna targets. Nucleic Acids Res. 2011, 39, 4827-4835.
113. Gu, S.; Jin, L.; Zhang, F.; Huang, Y.; Grimm, D.; Rossi, J.J.; Kay, M.A. Thermodynamic stability of small hairpin rnas highly influences the loading process of different mammalian argonautes. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 9208-9213.
114. Bartel, D. Micrornas: Target recognition and regulatory functions. Cell 2009, 136, 215-233.
115. Lewis, B.P.; Shih, I.H.; Jones-Rhoades, M.W.; Bartel, D.P.; Burge, C.B. Prediction of mammalian microrna targets. Cell 2003, 115, 787-798.
116. Lin, X.; Ruan, X.; Anderson, M.G.; Mcdowell, J.A.; Kroeger, P.E.; Fesik, S.W.; Shen, Y. Sirna-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 2005, 33, 4527.
117. Lai, E.C. Micro rnas are complementary to 3 ' utr sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet. 2002, 30, 363-364.
118. Schultz, N.; Marenstein, D.R.; De Angelis, D.A.; Wang, W.-Q.; Nelander, S.; Jacobsen, A.; Marks, D.S.; Massagué, J.; Sander, C. Off-target effects dominate a large-scale rnai screen for modulators of the tgf-β pathway and reveal microrna regulation of tgfbr2. Silence 2011, 2, 3.
119. Didiano, D.; Hobert, O. Perfect seed pairing is not a generally reliable predictor for mirna-target interactions. Nat. Struct. Mol. Biol. 2006, 13, 849-851.
120. Doench, J.G.; Sharp, P.A. Specificity of microrna target selection in translational repression. Genes Dev. 2004, 18, 504-511.
121. Broderick, J.A.; Salomon, W.E.; Ryder, S.P.; Aronin, N.; Zamore, P.D. Argonaute protein identity and pairing geometry determine cooperativity in mammalian rna silencing. RNA 2011, 17, 1858-1869.
122. Kozomara, A.; Griffiths-Jones, S. Mirbase: Integrating microrna annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39, D152-D157.
123. Sigoillot, F.D.; Lyman, S.; Huckins, J.F.; Adamson, B.; Chung, E.; Quattrochi, B.; King, R.W. A bioinformatics method identifies prominent off-targeted transcripts in rnai screens. Nat. Methods 2012, 9, 363-366.
124. Sudbery, I.; Enright, A.J.; Fraser, A.G.; Dunham, I. Systematic analysis of off-target effects in an rnai screen reveals micrornas affecting sensitivity to trail-induced apoptosis. BMC Genomics 2010, 11, 175.
125. Anderson, E.M.; Birmingham, A.; Baskerville, S.; Reynolds, A.; Maksimova, E.; Leake, D.; Fedorov, Y.; Karpilow, J.; Khvorova, A. Experimental validation of the importance of seed complement frequency to sirna specificity. RNA 2008, 14, 853-861.
126. Snove, O.; Holen, T. Many commonly used sirnas risk off-target activity. Biochem. Biophys. Res. Commun. 2004, 319, 256-263.
127. Holen, T.; Moe, S.E.; Sorbo, J.G.; Meza, T.J.; Ottersen, O.P.; Klungland, A. Tolerated wobble mutations in sirnas decrease specificity, but can enhance activity in vivo. Nucleic Acids Res. 2005,33, 4704-4710.
128. Schwarz, D.S.; Ding, H.; Kennington, L.; Moore, J.T.; Schelter, J.; Burchard, J.; Linsley, P.S.; Aronin, N.; Xu, Z.; Zamore, P.D. Designing sirna that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2006, 2, 1307-1318.
129. Jackson, A.L.; Burchard, J.; Schelter, J.; Chau, B.N.; Cleary, M.; Lim, L.; Linsley, P.S. Widespread sirna "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006,12, 1179-1187.
130. Saxena, S.; Jónsson, Z.O.; Dutta, A. Small rnas with imperfect match to endogenous mrna repress translation. Implications for off-target activity of small inhibitory rna in mammalian cells. J. Biol. Chem. 2003, 278, 44312-44319.
131. Scacheri, P.C.; Rozenblatt-Rosen, O.; Caplen, N.J.; Wolfsberg, T.G.; Umayam, L.; Lee, J.C.; Hughes, CM.; Shanmugam, K.S.; Bhattacharjee, A.; Meyerson, M. Short interfering rnas can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. USA 2004, 101, 1892-1897.
132. Aleman, L.M.; Doench, J.; Sharp, P.A. Comparison of sirna-induced off-target rna and protein effects. RNA 2007, 13, 385-395.
133. Liu, J.; Valencia-Sanchez, M.A.; Hannon, G.J.; Parker, R. Microrna-dependent localization of targeted mrnas to mammalian p-bodies. Nat. Cell Biol. 2005, 7, 719-723.
134. Teixeira, D.; Sheth, U.; Valencia-Sanchez, M.A.; Brengues, M.; Parker, R Processing bodies require rna for assembly and contain nontranslating mrnas. RNA 2005, 11, 371-382.
135. Behm-Ansmant, I.; Rehwinkel, J.; Izaurralde, E. Micrornas silence gene expression by repressing protein expression and/or by promoting mrna decay. Cold Spring Harb. Symp. Quant. Biol. 2006, 71, 523-530.
136. Semizarov, D.; Frost, L.; Sarthy, A; Kroeger, P.; Halbert, D.N.; Fesik, S.W. Specificity of short interfering rna determined through gene expression signatures. Proc. Natl. Acad. Sci. USA 2003, 100, 6347-6352.
137. Persengiev, S.P.; Zhu, X.; Green, M.R. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering rnas (sirnas). RNA 2004, 10, 12-18.
138. Wilson, P.A.; Plucinski, M. A simple bayesian estimate of direct rnai gene regulation events from differential gene expression profiles. BMC Genomics 2011, 12, 250.
139. Sydor, J.R; Nock, S. Protein expression profiling arrays: Tools for the multiplexed high-throughput analysis of proteins. Proteome Sci. 2003, 1, 3.
140. Pan, S.; Aebersold, R.; Chen, R.; Rush, J.; Goodlett, D.R.; McIntosh, M.W.; Zhang, J.; Brentnall, T.A. Mass spectrometry based targeted protein quantification: Methods and applications. J. Proteome Res. 2009, 8, 787-797.
141. Huang, H.; Qiao, R.; Zhao, D.; Zhang, T.; Li, Y.; Yi, F.; Lai, F.; Hong, J.; Ding, X.; Yang, Z, et al. Profiling of mismatch discrimination in rnai enabled rational design of allele-specific sirnas. Nucleic Acids Res. 2009, 37, 7560-7569.
142. Kittler, R.; Surendranath, V.; Heninger, A.-K.; Slabicki, M.; Theis, M.; Putz, G.; Franke, K.; Caldarelli, A.; Grabner, H.; Kozak, K, et al. Genome-wide resources of endoribonuclease-prepared short interfering rnas for specific loss-of-function studies. Nat. Methods 2007, 4, 337-344.
143. Parker, J.S.; Parizotto, E.A.; Wang, M.; Roe, S.M.; Barford, D. Enhancement of the seed-target recognition step in rna silencing by a piwi/mid domain protein. Mol. Cell 2009, 33, 204-214.
144. Birmingham, A.; Anderson, E.M.; Reynolds, A.; Ilsley-Tyree, D.; Leake, D.; Fedorov, Y.; Baskerville, S.; Maksimova, E.; Robinson, K.; Karpilow, J.; Marshall, W.S.; Khvorova, A. 3' UTR seed matches, but not overall identity, are associated with rnai off-targets. Nat. Methods 2006, 3, 199-204.
145. Boland, A.; Tritschler, F.; Heimst Auml Dt, S.; Izaurralde, E.; Weichenrieder, O. Crystal structure and ligand binding of the mid domain of a eukaryotic argonaute protein. EMBO Rep. 2010, 11, 522-527.
146. Ma, J.-B.; Ye, K.; Patel, D.J. Structural basis for overhang-specific small interfering rna recognition by the paz domain. Nature 2004, 429, 318-322.
147. Lingel, A.; Simon, B.; Izaurralde, E.; Sattler, M. Nucleic acid 3'-end recognition by the argonaute2 paz domain. Nat. Struct. Mol. Biol. 2004, 11, 576-577.
148. Sashital, D.G.; Doudna, J.A. Structural insights into rna interference. Curr. Opin. Struct. Biol. 2010, 20, 90-97.
149. Vert, J.-P.; Foveau, N.; Lajaunie, C.; Vandenbrouck, Y. An accurate and interpretable model for sirna efficacy prediction. BMC Bioinformatics 2006, 7, 520.
150. Patzel, V.; Rutz, S.; Dietrich, I.; Köberle, C.; Scheffold, A.; Kaufmann, S.H.E. Design of sirnas producing unstructured guide-rnas results in improved rna interference efficiency. Nat. Biotechnol. 2005, 23, 1440-1444.
151. Köberle, C.; Kaufmann, S.H.E.; Patzel, V. Selecting effective sirnas based on guide rna structure. Nat. Protoc. 2006, 1, 1832-1839.
152. Hossbach, M.; Gruber, J.; Osborn, M.; Weber, K.; Tuschl, T. Gene silencing with sirna duplexes composed of target-mrna-complementary and partially palindromic or partially complementary single-stranded sirnas. RNA Biol. 2006, 3, 82-89.
153. Vermeulen, A.; Behlen, L.; Reynolds, A.; Wolfson, A.; Marshall, W.S.; Karpilow, J.; Khvorova, A. The contributions of dsrna structure to dicer specificity and efficiency. RNA 2005, 11, 674-682.
154. Sciabola, S.; Cao, Q.; Orozco, M.; Faustino, I.; Stanton, R.V. Improved nucleic acid descriptors for sirna efficacy prediction. Nucleic Acids Res. 2012.
155. Snead, N.M.; Rossi, J.J. Rna interference trigger variants: Getting the most out of rna for rna interference-based therapeutics. Nucleic Acid Ther. 2012, 22, 139-146.
156. Martinez, J.; Patkaniowska, A.; Urlaub, H.; Lührmann, R.; Tuschl, T. Single-stranded antisense sirnas guide target rna cleavage in rnai. Cell 2002, 110, 563-574.
157. Holen, T.; Amarzguioui, M.; Babaie, E.; Prydz, H. Similar behaviour of single-strand and double-strand sirnas suggests they act through a common rnai pathway. Nucleic Acids Res. 2003, 31, 2401-2407.
158. Lima, W.F.; Prakash, T.P.; Murray, H.M.; Kinberger, G.A.; Li, W.; Chappell, A.E.; Li, C.S.; Murray, S.F.; Gaus, H.; Seth, P.P, et al. Single-stranded sirnas activate rnai in animals. Cell 2012, 150, 883-894.
159. Haringsma, H.J.; Li, J.J.; Soriano, F.; Kenski, D.M.; Flanagan, W.M.; Willingham, A.T. Mrna knockdown by single strand rna is improved by chemical modifications. Nucleic Acids Res. 2012, 40, 4125-4136.
160. Chu, C.-Y.; Rana, T.M. Potent rnai by short rna triggers. RNA 2008, 14, 1714-1719.
161. Sun, X.; Rogoff, H.A.; Li, C.J. Asymmetric rna duplexes mediate rna interference in mammalian cells. Nat. Biotechnol. 2008, 26, 1379-1382.
162. Chang, C.I.; Yoo, J.W.; Hong, S.W.; Lee, S.E.; Kang, H.S.; Sun, X.; Rogoff, H.A.; Ban, C.; Kim, S.; Li, C.J.; et al. Asymmetric shorter-duplex sirna structures trigger efficient gene silencing with reduced nonspecific effects. Mol. Ther. 2009, 17, 725-732.
163. Hohjoh, H. Enhancement of rnai activity by improved sirna duplexes. FEBS Lett. 2004, 557, 193-198.
164. Bramsen, J.B.; Laursen, M.B.; Damgaard, C.K.; Lena, S.W.; Babu, B.R.; Wengel, J.; Kjems, J. Improved silencing properties using small internally segmented interfering rnas. Nucleic Acids Res. 2007, 35, 5886-5897.
165. Dua, P.; Yoo, J.W.; Kim, S.; Lee, D.-K. Modified sirna structure with a single nucleotide bulge overcomes conventional sirna-mediated off-target silencing. Mol. Ther. 2011, 19, 1676-1687.
166. Amarzguioui, M.; Lundberg, P.; Cantin, E.; Hagstrom, J.; Behlke, M.A.; Rossi, J.J. Rational design and in vitro and in vivo delivery of dicer substrate sirna. Nat. Protoc. 2006, 1, 508-517.
167. Collingwood, M.A.; Rose, S.D.; Huang, L.; Hillier, C.; Amarzguioui, M.; Wiiger, M.T.; Soifer, H.S.; Rossi, J.J.; Behlke, M.A. Chemical modification patterns compatible with high potency dicer-substrate small interfering rnas. Oligonucleotides 2008, 18, 187-200.
168. Tanudji, M.; Machalek, D.; Arndt, G.M.; Rivory, L. Competition between sirna duplexes: Impact of rna-induced silencing complex loading efficiency and comparison between conventional-21 bp and dicer-substrate sirnas. Oligonucleotides 2010, 20, 27-32.
169. Foster, D.J.; Barros, S.; Duncan, R.; Shaikh, S.; Cantley, W.; Dell, A.; Bulgakova, E.; O'Shea, J.; Taneja, N.; Kuchimanchi, S, et al. Comprehensive evaluation of canonical versus dicer-substrate sirna in vitro and in vivo. RNA 2012, 18, 557-568.
170. Turner, J.J.; Jones, S.W.; Moschos, S.A.; Lindsay, M.A.; Gait, M.J. Maldi-tof mass spectral analysis of sirna degradation in serum confirms an rnase a-like activity. Mol. Biosyst. 2006, 3, 43-50.
171. Volkov, A.A.; Kruglova, N.y.S.; Meschaninova, M.I.; Venyaminova, A.G.; Zenkova, M.A.; Vlassov, V.V.; Chernolovskaya, E.L. Selective protection of nuclease-sensitive sites in sirna prolongs silencing effect. Oligonucleotides 2009, 19, 191-202.
172. Hong, J.; Huang, Y.; Li, J.; Yi, F.; Zheng, J.; Huang, H.; Wei, N.; Shan, Y.; An, M.; Zhang, H.; et al. Comprehensive analysis of sequence-specific stability of sirna. FASEB J. 2010, 24, 4844-4855.
173. Allerson, C.R.; Sioufi, N.; Jarres, R.; Prakash, T.P.; Naik, N.; Berdeja, A.; Wanders, L.; Griffey, R.H.; Swayze, E.E.; Bhat, B. Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering rna. J. Med. Chem. 2005, 48, 901-904.
174. Bramsen, J.B.; Laursen, M.B.; Nielsen, A.F.; Hansen, T.B.; Bus, C.; Langkjaer, N.; Babu, B.R.; Hojland, T.; Abramov, M.; Van Aerschot, A.; Odadzic, D, et al. A large-scale chemical modification screen identifies design rules to generate sirnas with high activity, high stability and low toxicity. Nucleic Acids Res. 2009, 37, 2867-2881.
175. Kenski, D.M.; Butora, G.; Willingham, A.T.; Cooper, A.J.; Fu, W.; Qi, N.; Soriano, F.; Davies, I.W.; Flanagan, W.M. Sirna-optimized modifications for enhanced in vivo activity. Mol. Ther. Nucleic Acids 2012, 1, e5.
176. Braasch, D.A.; Jensen, S.; Liu, Y.; Kaur, K.; Arar, K.; White, M.A.; Corey, D.R. Rna interference in mammalian cells by chemically-modified rna. Biochemistry 2003, 42, 7967-7975.
177. Chiu, Y.-L.; Rana, T.M. Sirna function in rnai: A chemical modification analysis. RNA 2003, 9, 1034-1048.
178. Manoharan, M.; Akinc, A.; Pandey, R.K.; Qin, J.; Hadwiger, P.; John, M.; Mills, K.; Charisse, K.; Maier, M.A.; Nechev, L, et al. Unique gene-silencing and structural properties of 2'-fluoro-modified sirnas. Angew. Chem. Int. Ed. Engl. 2011, 50, 2284-2288.
179. Cekaite, L.; Furset, G.; Hovig, E.; Sioud, M. Gene expression analysis in blood cells in response to unmodified and 2-modified sirnas reveals tlr-dependent and independent effects. J. Mol. Biol. 2007, 365, 90-108.
180. Tluk, S.; Jurk, M.; Forsbach, A.; Weeratna, R.; Samulowitz, U.; Krieg, A.M.; Bauer, S.; Vollmer, J. Sequences derived from self-rna containing certain natural modifications act as suppressors of rna-mediated inflammatory immune responses. Int. Immunol. 2009, 21, 607-619.
181. Fucini, R.V.; Haringsma, H.J.; Deng, P.; Flanagan, W.M.; Willingham, A.T. Adenosine modification may be preferred for reducing sirna immune stimulation. Nucleic Acid Ther. 2012, 22, 205-210.
182. Haupenthal, J.; Baehr, C.; Kiermayer, S.; Zeuzem, S.; Piiper, A. Inhibition of rnase a family enzymes prevents degradation and loss of silencing activity of sirnas in serum. Biochem. Pharmacol. 2006, 71, 702-710.
183. Amarzguioui, M. Tolerance for mutations and chemical modifications in a sirna. Nucleic Acids Res. 2003, 31, 589-595.
184. Yang, X.; Sierant, M.; Janicka, M.; Peczek, L.; Martinez, C.; Hassell, T.; Li, N.; Li, X.; Wang, T.; Nawrot, B. Gene silencing activity of sirna molecules containing phosphorodithioate substitutions. ACS Chem. Biol. 2012, 7, 1214-1220.
185. Bramsen, J.B.; Kjems, J. Development of therapeutic-grade small interfering rnas by chemical engineering. Front. Genet. 2012, 3, 154-154.
186. Wang, J.; Byrne, J.D.; Napier, M.E.; DeSimone, J.M. More effective nanomedicines through particle design. Small 2011, 7, 1919-1931.
187. Elsabahy, M.; Wooley, K.L. Design of polymeric nanoparticles for biomedical delivery applications. Chem. Soc. Rev. 2012, 41, 2545-2561.
188. Siegwart, D.J.; Whitehead, K.A.; Nuhn, L.; Sahay, G.; Cheng, H.; Jiang, S.; Ma, M.; Lytton-Jean, A.; Vegas, A.; Fenton, P, et al. Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery. Proc. Natl. Acad. Sci. USA 2011, 108, 12996-13001.
189. Ulery, B.D.; Nair, L.S.; Laurencin, C.T. Biomedical applications of biodegradable polymers. J. Polym. Sci. B Polym. Phys. 2011, 49, 832-864.
190. Whitehead, K.A.; Sahay, G.; Li, G.Z.; Love, K.T.; Alabi, C.A.; Ma, M.; Zurenko, C.; Querbes, W.; Langer, R.S.; Anderson, D.G. Synergistic silencing: Combinations of lipid-like materials for efficacious sirna delivery. Mol. Ther. 2011, 19, 1688-1694.
191. Semple, S.C.; Akinc, A.; Chen, J.; Sandhu, A.P.; Mui, B.L.; Cho, C.K.; Sah, D.W.Y.; Stebbing, D.; Crosley, E.J.; Yaworski, E, et al. Rational design of cationic lipids for sirna delivery. Nat. Biotechnol. 2010, 28, 172-176.
192. Malam, Y.; Loizidou, M.; Seifalian, A.M. Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30, 592-599.
193. Mutlu, G.M.; Budinger, G.R.S.; Green, A.A.; Urich, D.; Soberanes, S.; Chiarella, S.E.; Alheid, G.F.; McCrimmon, D.R.; Szleifer, I.; Hersam, M.C. Biocompatible nanoscale dispersion of single-walled carbon nanotubes minimizes in vivo pulmonary toxicity. Nano Lett. 2010, 10, 1664-1670.
194. Cheung, W.; Pontoriero, F.; Taratula, O.; Chen, A.M.; He, H.X. DNA and carbon nanotubes as medicine. Adv. Drug Deliv. Rev. 2010, 62, 633-649.
195. Dobrovolskaia, M.A.; Aggarwal, P.; Hall, J.B.; McNeil, S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 2008, 5, 487-495.
196. Li, Y.; Sun, L.; Jin, M.; Du, Z.; Liu, X.; Guo, C.; Li, Y.; Huang, P.; Sun, Z. Size-dependent cytotoxicity of amorphous silica nanoparticles in human hepatoma hepg2 cells. Toxicol. In Vitro 2011, 25, 1343-1352.
197. Slowing, I.I.; Trewyn, B.G.; Giri, S.; Lin, V.S.Y. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv. Funct. Mater. 2007, 17, 1225-1236.
198. Asefa, T.; Tao, Z. Biocompatibility of mesoporous silica nanoparticles. Chem. Res. Toxicol. 2012,25, 2265-2284.
199. Colombo, M.; Carregal-Romero, S.; Casula, M.F.; Gutierrez, L.; Morales, M.P.; Bohm, I.B.; Heverhagen, J.T.; Prosperi, D.; Parak, W.J. Biological applications of magnetic nanoparticles. Chem. Soc. Rev. 2012, 41, 4306-4334.
200. Prijic, S.; Sersa, G. Magnetic nanoparticles as targeted delivery systems in oncology. Radiol. Oncol. 2011, 45, 1-16.
201. Khlebtsov, N.; Dykman, L. Biodistribution and toxicity of engineered gold nanoparticles: A review of in vitro and in vivo studies. Chem. Soc. Rev. 2011, 40, 1647-1671.
202. Cho, E.C.; Zhang, Q.; Xia, Y. The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat. Nanotechnol. 2011, 6, 385-391.
203. Kong, W.H.; Bae, K.H.; Jo, S.D.; Kim, J.S.; Park, T.G. Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular sirna delivery vehicles. Pharm. Res. 2012, 29, 362-374.
204. Daka, A.; Peer, D. Rnai-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev. 2012, 64, 1508-1521.
205. Parveen, S.; Misra, R.; Sahoo, S.K. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012, 8, 147-166.
206. Burnett, J.C.; Rossi, J.J. Rna-based therapeutics: Current progress and future prospects. Chem. Biol. 2012, 19, 60-71.
207. De Ilarduya, C.T.; Sun, Y.; Duezguenes, N. Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci. 2010, 40, 159-170.
208. De Planque, M.R.R.; Aghdaei, S.; Roose, T.; Morgan, H. Electrophysiological characterization of membrane disruption by nanoparticles. ACS Nano 2011, 5, 3599-3606.
209. Khalil, I.A.; Kogure, K.; Akita, H.; Harashima, H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 2006, 58, 32-45.
210. Ding, H.M.; Tian, W.D.; Ma, Y.Q. Designing nanoparticle translocation through membranes by computer simulations. ACS Nano 2012, 6, 1230-1238.
211. Huotari, J.; Helenius, A. Endosome maturation. EMBO J. 2011, 30, 3481-3500.
212. Doherty, G.J.; McMahon, H.T. Mechanisms of endocytosis. Annu. Rev. Biochem. 2009, 78, 857-902.
213. Kerr, M.C.; Teasdale, R.D. Defining macropinocytosis. Traffic 2009, 10, 364-371.
214. Mayor, S.; Pagano, R.E. Pathways of clathrin-independent endocytosis. Nat. Rev. Mol. Cell Biol. 2007, 8, 603-612.
215. Rejman, J.; Bragonzi, A.; Conese, M. Role of clathrin-and caveolae-mediated endocytosis in gene transfer mediated by lipo-and polyplexes. Mol. Ther. 2005, 12, 468-474.
216. Frohlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomedicine 2012, 7, 5577-5591.
217. Goncalves, C.; Mennesson, E.; Fuchs, R.; Gorvel, J.P.; Midoux, P.; Pichon, C. Macropinocytosis of polyplexes and recycling of plasmid via the clathrin-dependent pathway impair the transfection efficiency of human hepatocarcinoma cells. Mol. Ther. 2004, 10, 373-385.
218. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2002, 54, 631-651.
219. Moghimi, S.M.; Hunter, A.C.; Andresen, T.L. Factors controlling nanoparticle pharmacokinetics: An integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 481-503.
220. Venturoli, D.; Rippe, B. Ficoll, and dextran VS. Globular proteins as probes for testing glomerular permselectivity: Effects of molecular size, shape, charge, and deformability. Am. J. Physiol. Renal Physiol. 2005, 288, F605-F613.
221. Petros, R.A.; DeSimone, J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9, 615-627.
222. Allen, T.M.; Cullis, P.R. Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818-1822.
223. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006, 27, 4356-4373.
224. Doshi, N.; Mitragotri, S. Macrophages recognize size and shape of their targets. PLoS ONE 2010, 5, e10051.
225. Decuzzi, P.; Pasqualini, R.; Arap, W.; Ferrari, M. Intravascular delivery of particulate systems: Does geometry really matter? Pharm. Res. 2009, 26, 235-243.
226. Champion, J.A.; Mitragotri, S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. USA 2006, 103, 4930-4934.
227. He, C.; Hu, Y.; Yin, L.; Tang, C.; Yin, C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31, 3657-3666.
228. Galvin, P.; Thompson, D.; Ryan, K.B.; McCarthy, A.; Moore, A.C.; Burke, C.S.; Dyson, M.; MacCraith, B.D.; Gun'ko, Y.K.; Byrne, M.T, et al. Nanoparticle-based drug delivery: Case studies for cancer and cardiovascular applications. Cell. Mol. Life Sci. 2012, 69, 389-404.
229. Schipper, M.L.; Iyer, G.; Koh, A.L.; Cheng, Z.; Ebenstein, Y.; Aharoni, A.; Keren, S.; Bentolila, L.A.; Li, J.Q.; Rao J.H, et al. Particle size, surface coating, and pegylation influence the biodistribution of quantum dots in living mice. Small 2009, 5, 126-134.
230. Lemarchand, C.; Gref, R.; Couvreur, P. Polysaccharide-decorated nanoparticles. Eur. J. Pharm. Biopharm. 2004, 58, 327-341.
231. Dufort, S.; Sancey, L.; Coll, J.L. Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv. Drug Deliv. Rev. 2012, 64, 179-189.
232. Noguchi, Y.; Wu, J.; Duncan, R.; Strohalm, J.; Ulbrich, K.; Akaike, T.; Maeda, H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 1998, 89, 307-314.
233. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the epr effect in macromolecular therapeutics: A review. J. Control. Release 2000, 65, 271-284.
234. Byrne, J.D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60, 1615-1626.
235. Singh, S.; Sharma, A.; Robertson, G.P. Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res. 2012, 72, 5663-5668.
236. Lo, A.; Lin, C.-T.; Wu, H.-C. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol. Cancer Ther. 2008, 7, 579-589.
237. Yan, H.B.; Tram, K. Glycotargeting to improve cellular delivery efficiency of nucleic acids. Glycoconj. J. 2007, 24, 107-123.
238. Vaishnaw, A.K.; Gollob, J.; Gamba-Vitalo, C.; Hutabarat, R.; Sah, D.; Meyers, R.; de Fougerolles, T.; Maraganore, J. A status report on rnai therapeutics. Silence 2010, 1, 14.
239. De Fougerolles, A.R. Delivery vehicles for small interfering rna in vivo. Hum. Gene Ther. 2008, 19, 125-132.
240. Wu, Y.; Ho, Y.P.; Mao, Y.C.; Wang, X.M.; Yu, B.; Leong, K.W.; Lee, L.J. Uptake and intracellular fate of multifunctional nanoparticles: A comparison between lipoplexes and polyplexes via quantum dot mediated forster resonance energy transfer. Mol. Pharm. 2011, 8, 1662-1668.
241. Strumberg, D.; Schultheis, B.; Traugott, U.; Vank, C.; Santel, A.; Keil, O.; Giese, K.; Kaufmann, J.; Drevs, J. Phase i clinical development of atu027, a sirna formulation targeting pkn3 in patients with advanced solid tumors. Int. J. Clin. Pharmacol. Ther. 2012, 50, 76-78.
242. Lonez, C.; Vandenbranden, M.; Ruysschaert, J.M. Cationic liposomal lipids: From gene carriers to cell signaling. Prog. Lipid Res. 2008, 47, 340-347.
243. Barros, S.A.; Gollob, J.A. Safety profile of rnai nanomedicines. Adv. Drug Deliv. Rev. 2012, 64, 1730-1737.
244. Davis, M.E. The first targeted delivery of sirna in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharm. 2009, 6, 659-668.
245. Heidel, J.D.; Davis, M.E. Clinical developments in nanotechnology for cancer therapy. Pharm. Res. 2011,28, 187-199.
246. Rozema, D.B.; Lewis, D.L.; Wakefield, D.H.; Wong, S.C.; Klein, J.J.; Roesch, P.L.; Bertin, S.L.; Reppen, T.W.; Chu, Q.; Blokhin A.V, et al. Dynamic polyconjugates for targeted in vivo delivery of sirna to hepatocytes. Proc. Natl. Acad. Sci. USA 2007, 104, 12982-12987.
247. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55, 329-347.
248. Reilly, M.J.; Larsen, J.D.; Sullivan, M.O. Histone h3 tail peptides and poly(ethylenimine) have synergistic effects for gene delivery. Mol. Pharm. 2012, 9, 1031-1040.
249. Zhou, J.; Liu, J.; Cheng, C.J.; Patel, T.R.; Weller, C.E.; Piepmeier, J.M.; Jiang, Z.; Saltzman, W.M. Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nat. Mater.2012, 11, 82-90.